Free Trial
NASDAQ:DTIL

Precision BioSciences Q3 2025 Earnings Results & Report

Precision BioSciences logo
$7.57 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$7.58 +0.00 (+0.07%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 3, 2025. The company reported EPS of -$1.84 versus the -$0.31 consensus estimate, while revenue of $13 thousand fell short of the $5.40 million estimate by $5.39 million.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
12:30 PM ET

Precision BioSciences EPS Results

Actual EPS
-$1.84
Consensus EPS
-$0.31
Beat/Miss
Missed by -$1.53
One Year Ago EPS
-$2.25
EPS Beat Rate
2 of last 8 quarters

Precision BioSciences Revenue Results

Actual Revenue
$13 thousand
Expected Revenue
$5.40 million
Beat/Miss
Missed by -$5.39 million
YoY Revenue Growth
N/A

Precision BioSciences Q3 2025 Earnings FAQ

Precision BioSciences (NASDAQ:DTIL) reported earnings of -$1.84 per share for Q3 2025, missing the consensus estimate of -$0.31. The report was announced on Monday, November 3, 2025.

Precision BioSciences reported revenue of $13 thousand for Q3 2025, against a consensus estimate of $5.40 million.

Precision BioSciences Earnings Headlines

HC Wainwright Has Bullish Estimate for DTIL FY2026 Earnings
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Precision BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email.

About Precision BioSciences

Precision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases.

The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences has also pursued applications of its gene-editing technology through collaborations and licensing arrangements.

View Precision BioSciences Profile